Mirum Pharmaceuticals (MIRM) Accumulated Expenses (2018 - 2026)

Mirum Pharmaceuticals' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $187.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 61.83% year-over-year to $187.6 million; the TTM figure through Mar 2026 stood at $187.6 million (up 61.83% YoY), while the FY2025 annual figure was $196.2 million, up 75.27% from the prior year.
• Accumulated Expenses was $187.6 million for Q1 2026 at Mirum Pharmaceuticals, down from $196.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $196.2 million in Q4 2025 to a low of $1.6 million in Q3 2022.
• Historically, Accumulated Expenses has averaged $82.8 million across 5 years, with a median of $89.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses slumped 96.25% in 2022, then surged 3925.11% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $2.5 million in 2022, then soared by 3098.05% to $78.5 million in 2023, then surged by 42.51% to $111.9 million in 2024, then soared by 75.27% to $196.2 million in 2025, then slipped by 4.36% to $187.6 million in 2026.
• The last three Accumulated Expenses figures came in at $187.6 million (Q1 2026), $196.2 million (Q4 2025), and $148.2 million (Q3 2025), per Business Quant data.